"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Descriptor ID |
D011960
|
MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 12 | 9 | 21 |
1995 | 9 | 7 | 16 |
1996 | 4 | 6 | 10 |
1997 | 9 | 11 | 20 |
1998 | 8 | 11 | 19 |
1999 | 9 | 9 | 18 |
2000 | 16 | 12 | 28 |
2001 | 17 | 13 | 30 |
2002 | 10 | 11 | 21 |
2003 | 19 | 20 | 39 |
2004 | 17 | 20 | 37 |
2005 | 22 | 30 | 52 |
2006 | 18 | 23 | 41 |
2007 | 25 | 18 | 43 |
2008 | 12 | 18 | 30 |
2009 | 18 | 24 | 42 |
2010 | 30 | 25 | 55 |
2011 | 22 | 37 | 59 |
2012 | 26 | 38 | 64 |
2013 | 14 | 29 | 43 |
2014 | 14 | 30 | 44 |
2015 | 16 | 23 | 39 |
2016 | 10 | 16 | 26 |
2017 | 10 | 27 | 37 |
2018 | 8 | 22 | 30 |
2019 | 12 | 15 | 27 |
2020 | 8 | 19 | 27 |
2021 | 10 | 17 | 27 |
2022 | 3 | 16 | 19 |
2023 | 2 | 13 | 15 |
2024 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer. Cancer Res Commun. 2024 02 22; 4(2):496-504.
-
The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. Breast Cancer Res. 2024 02 05; 26(1):23.
-
TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Arch Pathol Lab Med. 2024 Feb 01; 148(2):200-205.
-
Analysis of Breast Cancer Mortality in the US-1975 to 2019. JAMA. 2024 01 16; 331(3):233-241.
-
Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer. Ann Surg Oncol. 2024 Apr; 31(4):2244-2252.
-
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024 Jan 16; 149(3):227-250.
-
Gene transcription regulation by ER at the single cell and allele level. Steroids. 2023 Dec; 200:109313.
-
Cellular and extracellular vaginal changes following murine ovarian removal. Physiol Rep. 2023 08; 11(15):e15762.
-
Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes. Breast Cancer Res Treat. 2023 Nov; 202(2):367-375.